Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Toradol "Dear Doctor" letter cites inappropriate use uncovered by postmarketing study.

Executive Summary

ROCHE TORADOL "DEAR DOCTOR" LETTER CITES INAPPROPRIATE USE seen in a 10,000 patient postmarketing study conducted by Roche's Syntex subsidiary. The letter, disclosed by Roche on Feb. 23, was sent to 60,000 physicians. The postmarketing study found physicians prescribing the nonsteroidal anti-inflammatory drug Toradol (ketorolac) to NSAID-sensitive patients; to patients with gastrointestinal bleeding; to elderly or renally impaired patients without proper dose modification; and for long-term use of Toradol tablets, the letter reports.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel